Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

PubWeight™: 5.96‹?› | Rank: Top 1%

🔗 View Article (PMID 15383479)

Published in Chest on September 01, 2004


Harry R Büller1, Giancarlo Agnelli, Russel D Hull, Thomas M Hyers, Martin H Prins, Gary E Raskob

Author Affiliations

1: Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Articles citing this

(truncated to the top 100)

Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ (2007) 3.26

Improving the use of research evidence in guideline development: 10. Integrating values and consumer involvement. Health Res Policy Syst (2006) 2.93

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54

The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med (2006) 2.21

Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am (2007) 2.17

Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations. Health Res Policy Syst (2006) 1.80

Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis (2009) 1.71

Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71

Venous thromboembolism-related mortality and morbidity in King Fahd General Hospital, Jeddah, Kingdom of Saudi Arabia. Ann Thorac Med (2011) 1.56

Enlarged right ventricle without shock in acute pulmonary embolism: prognosis. Am J Med (2008) 1.55

Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35

Noninvasive treatment of deep venous thrombosis using pulsed ultrasound cavitation therapy (histotripsy) in a porcine model. J Vasc Interv Radiol (2010) 1.30

Cancer-associated thrombosis: an overview. Clin Med Insights Oncol (2014) 1.23

Venous thromboembolic disease and cancer. Postgrad Med J (2006) 1.23

Thrombosis associated with right internal jugular central venous catheters: A prospective observational study. Indian J Crit Care Med (2012) 1.13

Upper extremity deep vein thrombosis: a community-based perspective. Am J Med (2007) 1.11

Development and validation of a primary care-based family health history and decision support program (MeTree). N C Med J (2013) 1.07

Cerebral vein thrombosis misdiagnosed and mismanaged. Thrombosis (2012) 1.03

EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study. J Gen Intern Med (2008) 1.03

Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer (2008) 1.02

Pulmonary hypertension in pregnancy: critical care management. Pulm Med (2012) 0.97

Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One (2012) 0.96

Inferior vena cava filters for recurrent thrombosis: current evidence. Tex Heart Inst J (2007) 0.96

Acute pulmonary embolism. Part 2: treatment. Nat Rev Cardiol (2010) 0.96

Cancer-associated thrombosis: prevention and treatment. Curr Oncol (2008) 0.95

Evidence-based approach to thrombophilia testing. J Thromb Thrombolysis (2011) 0.93

Comorbidity in inflammatory bowel disease. World J Gastroenterol (2011) 0.93

Intracranial dural sinus thrombosis: novel use of a mechanical thrombectomy catheter and review of management strategies. Clin Med Res (2009) 0.93

Effectiveness of d-dimer as a screening test for venous thromboembolism: an update. N Am J Med Sci (2014) 0.92

Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. Eur J Clin Pharmacol (2013) 0.90

Optional vena cava filters: indications, management, and results. Dtsch Arztebl Int (2009) 0.89

Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist (2012) 0.88

Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology. Nat Clin Pract Oncol (2008) 0.87

Successful thrombolysis of right atrial and ventricular thrombi in a patient with massive pulmonary embolism. Hippokratia (2009) 0.87

Thrombolysis for massive pulmonary embolism in pregnancy: a case report. Int J Emerg Med (2011) 0.87

Comparison of low-molecular-weight-heparin and unfractionated heparin for acute PTE. J Zhejiang Univ Sci B (2005) 0.86

Clinical evidence for rebound hypercoagulability after discontinuing oral anticoagulants for venous thromboembolism. Medscape J Med (2008) 0.86

Arterial pulmonary hypertension in noncardiac intensive care unit. Vasc Health Risk Manag (2008) 0.86

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol (2009) 0.86

Essay for the CIHR/CMAJ award: the role of low-molecular-weight heparin therapy venous thromboembolism. CMAJ (2011) 0.85

Thrombolytic therapy complemented by ECMO: successful treatment for a case of massive pulmonary thromboembolism with hemodynamic collapse. J Korean Med Sci (2014) 0.84

Thrombolytic treatment (alteplase; rt-Pa) in acute massive pulmonary embolism and cardiopulmonary arrest. Drug Des Devel Ther (2014) 0.83

Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial. BMC Cardiovasc Disord (2007) 0.83

Open pulmonary thromboembolectomy in patients with major pulmonary thromboembolism. Yonsei Med J (2008) 0.83

[Pulmonary embolism]. Wien Med Wochenschr (2008) 0.82

Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Support Care Cancer (2008) 0.82

Effectiveness of warfarin among patients with cancer. J Gen Intern Med (2007) 0.81

Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review. Arq Bras Cardiol (2015) 0.81

Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. Br J Clin Pharmacol (2009) 0.81

Cancer-associated thrombosis. Open Cardiovasc Med J (2010) 0.80

Inferior vena caval filters: 5 years of experience in a tertiary care center. Ann Saudi Med (2009) 0.80

Cancer and thrombosis: an increasingly important association. Support Care Cancer (2008) 0.80

Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment. Rev Urol (2010) 0.79

Ambulation after deep vein thrombosis: a systematic review. Physiother Can (2009) 0.79

Outcomes of catheter-directed treatment of lower extremity deep vein thrombosis of patients presenting to a tertiary care hospital. Indian J Radiol Imaging (2016) 0.79

No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial. BMC Pulm Med (2010) 0.79

An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. Eur J Clin Pharmacol (2014) 0.78

Management of venous thromboembolism: why not treat it at home? Can Fam Physician (2005) 0.78

Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag (2008) 0.78

Experimental model of large pulmonary embolism employing controlled release of subacute caval thrombus in swine. J Vasc Interv Radiol (2011) 0.78

Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines. Thromb J (2008) 0.78

Technical Note: Contrast free angiography of the pulmonary vasculature in live mice using a laboratory x-ray source. Med Phys (2016) 0.77

Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. Eur J Clin Pharmacol (2006) 0.77

Accuracy of D-Dimers to Rule Out Venous Thromboembolism Events across Age Categories. Emerg Med Int (2010) 0.77

The predictive factors of recurrent deep vein thrombosis. ARYA Atheroscler (2011) 0.77

Prevention and treatment of venous thromboembolism in the elderly patient. Clin Interv Aging (2007) 0.77

Controversies in the antiphospholipid syndrome: can we ever stop warfarin? J Autoimmune Dis (2008) 0.77

Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? A qualitative study. BMC Med Inform Decis Mak (2012) 0.77

Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol (2008) 0.77

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77

Should symptomatic, isolated distal deep vein thrombosis be treated with anticoagulation? Int J Angiol (2009) 0.76

The Risk-based Treatment of Acute Pulmonary Embolism. J Clin Med Res (2009) 0.76

Cardiological evaluation after cerebral ischaemia : Consensus statement of the Working Group Heart and Brain of the German Cardiac Society-Cardiovascular Research (DGK) and the German Stroke Society (DSG). Clin Res Cardiol (2010) 0.76

Statistician expert witnesses in agreement on relative hazards. Clin Risk (2012) 0.75

Differences in the INR evaluation of two different thromboplastins in patients with positivity to lupus anticoagulant in ongoing oral anticoagulation. J Blood Med (2010) 0.75

International guidelines: Adoption or adaptation by the Saudi Heart Association? J Saudi Heart Assoc (2009) 0.75

Implant surgery and oral anticoagulant therapy: case report. Oral Implantol (Rome) (2014) 0.75

Duration of warfarin in pulmonary embolism. Chest (2006) 0.75

Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series. Clin Kidney J (2013) 0.75

Management of cancer-associated venous thrombosis. Vasc Health Risk Manag (2006) 0.75

Clinical utility of a Web-enabled risk-assessment and clinical decision support program. Genet Med (2016) 0.75

Nontreatment of deep vein thrombosis. Can Fam Physician (2005) 0.75

Vena cava thrombosis after vena cava filter placement: Incidence and risk factors. J Geriatr Cardiol (2011) 0.75

Contrast enhanced pulmonary magnetic resonance angiography for pulmonary embolism: Building a successful program. Eur J Radiol (2015) 0.75

The treatment of deep vein thrombosis in the pelvis and leg. Dtsch Arztebl Int (2008) 0.75

Correspondence (reply): In Reply. Dtsch Arztebl Int (2008) 0.75

Evaluation of computed tomography obstruction index in guiding therapeutic decisions and monitoring percutanous catheter fragmentation in massive pulmonary embolism. J Biomed Res (2011) 0.75

Management of venous thromboembolism in patients with cancer: role of dalteparin. Vasc Health Risk Manag (2008) 0.75

Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis. Thrombosis (2010) 0.75

Evaluation of the Management of Acute Venous Thromboembolism and Its Outcomes: One Institution's Experience. P T (2008) 0.75

Antiphospholipid syndrome and recurrent thrombosis--limitations of current treatment strategies. BMJ Case Rep (2012) 0.75

Upper-extremity deep-vein thrombosis in an elderly man. CMAJ (2007) 0.75

Heparin anticoagulation responsiveness in a coronary care unit: a prospective observational study. Cardiovasc Ther (2009) 0.75

Function of the Günther Tulip vena caval filter. Chest (2005) 0.75

Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada. Can J Hosp Pharm (2009) 0.75

From Pulmonary Embolism to Inflammatory Bowel Disease; Give Tunnel Vision up. Emerg (Tehran) (2016) 0.75

Percutaneous options for acute deep vein thrombosis. Semin Intervent Radiol (2005) 0.75

Recombinant tissue plasminogen activator for massive pulmonary thromboembolism. BMJ Case Rep (2013) 0.75

Evidence for treatment of muscular vein thrombosis in orthopaedic patients. J Orthop Traumatol (2013) 0.75

Linear polyalkylamines as fingerprinting agents in capillary electrophoresis of low-molecular-weight heparins and glycosaminoglycans. Electrophoresis (2011) 0.75

Articles by these authors

Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86

Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med (2012) 10.64

Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92

Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76

The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol (2003) 7.54

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12

Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00

2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32

Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41

Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA (2006) 4.75

Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72

Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52

Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46

Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37

Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08

Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med (2002) 3.91

ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood (2003) 3.88

Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med (2004) 3.74

Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost (2007) 3.67

Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ (2006) 3.58

Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51

A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg (2014) 3.43

An association between atherosclerosis and venous thrombosis. N Engl J Med (2003) 3.39

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ (2011) 3.28

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest (2010) 3.02

Left bundle-branch block induced by transcatheter aortic valve implantation increases risk of death. Circulation (2012) 2.95

Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90

Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol (2006) 2.84

Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens (2004) 2.71

Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation (2004) 2.69

Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke (2007) 2.60

Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59

Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation (2007) 2.54

Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events. Eur Heart J (2010) 2.52

Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation (2007) 2.51

Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ (2012) 2.38

Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med (2011) 2.34

The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med (2003) 2.33

Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. Ann Intern Med (2003) 2.33

Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med (2005) 2.32

The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31

Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology (2005) 2.30

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30

Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest (2004) 2.30

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet (2011) 2.24

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21

Safely ruling out deep venous thrombosis in primary care. Ann Intern Med (2009) 2.16

Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med (2002) 2.16

Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol (2005) 2.14

Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (2012) 2.13

Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol (2003) 2.13

Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet (2011) 2.09

Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood (2009) 1.93

Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest (2006) 1.85

Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84

Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med (2007) 1.84

Single-detector helical computed tomography as the primary diagnostic test in suspected pulmonary embolism: a multicenter clinical management study of 510 patients. Ann Intern Med (2003) 1.83

A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J (2004) 1.80

A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg (2002) 1.79

Anticoagulants in heart disease: current status and perspectives. Eur Heart J (2007) 1.73

Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res (2009) 1.72

A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood (2008) 1.70

A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med (2012) 1.67

Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace (2012) 1.67

Electronic monitoring of adherence as a tool to improve blood pressure control. A randomized controlled trial. Am J Hypertens (2007) 1.66

Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J (2008) 1.64

Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke (2008) 1.63

Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood (2011) 1.63

Perioperative blood transfusions and delayed wound healing after hip replacement surgery: effects on duration of hospitalization. Anesth Analg (2005) 1.60

The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace (2010) 1.59

Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood (2002) 1.59

Association of persistent right ventricular dysfunction at hospital discharge after acute pulmonary embolism with recurrent thromboembolic events. Arch Intern Med (2006) 1.56

Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J Vasc Surg (2010) 1.56

Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med (2008) 1.54

Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev (2014) 1.52

Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation (2010) 1.50

Probiotics versus antibiotic decontamination of the digestive tract: infection and mortality. Intensive Care Med (2010) 1.50

Does fast-track treatment lead to a decrease of intensive care unit and hospital length of stay in coronary artery bypass patients? A meta-regression of randomized clinical trials. Crit Care Med (2006) 1.49

Clinical and echocardiographic correlates of intra-atrial conduction delay. Europace (2011) 1.45

Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes (2010) 1.44